Stockreport

Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

Compugen Ltd. - Ordinary Shares  (CGEN) 
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: cgen.com/investors/overview
PDF HOLON, Israel, Nov. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, toda [Read more]